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During the past decade, immunother-
apy has emerged as a powerful modality to 
treat aggressive neoplasmsfor which a few 
(if any) curative treatment modalities are 
currently available. Cell-based immuno-
therapies, including the adoptive transfer 
of tumor-infiltrating lymphocytes, den-
dritic cell (DC)-based vaccines and T cells 
expressing recombinant tumor-specific 
T-cell receptors (TCRs) or chimeric anti-
gen receptors (CARs), showed promising 
results in both pre-clinical and clinical 
settings. Nevertheless, the widespread 
application of these strategies to treat can-
cer is hindered by several factors.1 Along 
similar lines, the administration of cyto-
toxic T lymphocyte-associated protein 4 
(CTLA4)-targeting antibodies (such as 
Ipilimumab) to patients with advanced 
melanoma appears to be particularly 
effective in the elicitation of tumor-spe-
cific immune responses. However, severe 
adverse events related to the unspecific 
activation of T cells at the systemic level 
(and hence to the elicitation of autoim-
mune reactions) remain a barrier to the 
widespread application of this immuno-
therapeutic regimen.2 Active vaccination 
protocols based on tumor-associated anti-
gens, including peptide- and DNA-based 
vaccines, have also been tested in differ-
ent pre-clinical and clinical settings.3 
Although these approaches offer multiple 
advantages and have been associated with 
antineoplastic activity in pre-clinical 
settings, the lack of efficacy in clinical 
scenarios offsets the advantages of pep-
tide- and DNA-based anticancer vaccines. 
Hence, there is an unmet need to improve 
these approaches to achieve adequate acti-
vation of tumor-specific immunity and 
clinically significant outcomes.
Multiple studies demonstrated that 
recruitment of different subsets of leu-
kocytes to neoplastic lesions facilitates 
recognition and elimination of malig-
nant lesions. As we had previously 
observed that elevated intratumoral lev-
els of a secondary lymphoid chemokine, 
CCL21effectively recruit T cells to the 
deep recesses of melanoma mass, hence 
boosting tumor elimination,4 we hypoth-
esized that altering chemotactic gradients 
within established tumors would improve 
the therapeutic efficacy of anticancer vac-
cines. Consistently,  we recently reported a 
significantly greater tumor growth inhibi-
tion in CCL21-primed tumors following 
DNA vaccination (Fig. 1A).5 This vacci-
nation protocol resulted in the regression 
of the pre-established melanomas associ-
ated with generation and expansion of the 
intratumoral antigen (Ag)-specific cyto-
toxic T cells (CTL)  (Fig. 1A).
Two distinct components of this immu-
notherapeutic regimen favorably influ-
enced its outcome: the composition of the 
DNA-based vaccine and the priming of 
neoplastic lesions with chemokines. In our 
hands, administration of a fusion protein 
containing the pan DR epitope (PADRE), 
which enhances activation of helper, effec-
tor and memory CD8+ T cells in mice 
and humans,6,7 was critical for the activa-
tion of tumor-specific immune response. 
On the other hand, priming of neoplastic 
lesions with selected chemokines, namely, 
CCL20 and CCL21 (alone or in combina-
tion), led to somehow contrasting results. 
Indeed, while the expression of CCL20 
was expected to recruit immature DCs 
and promote both antigen uptake and acti-
vation of tumor-specific T cells, elevated 
levels of this chemokine led to the recruit-
ment of regulatory T cells, which inhib-
ited vaccine-elicited immune response. 
On the contrary, priming of melanoma 
lesions with CCL21 alone resulted in the 
activation of superior melanoma-specific 
immune response. Although we and oth-
ers have previously demonstrated that 
a permanent intratumoral gradient of 
CCL21 facilitates recognition of malig-
nant cells by the immune system,4 our 
recent findings demonstrated that even 
a transient gradient of this chemokine 
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established prior to DNA vaccination 
favors the accumulation, activation and 
expansion of tumor-specific T cells.5 This 
is consistent with previous data demon-
strating that CCL21 can promote the 
clonal expansion of T cells.8 Thus, our 
data clearly demonstrate the efficacy of 
priming malignant lesions with specific 
chemokines prior to the administration 
of a therapeutic DNAanticancer vaccine. 
The optimization of this approach is likely 
to result in the development of a generic 
and cost-effective immunotherapeutic 
regimen for the treatment of unresectable 
(metastatic) tumors.
Currently, DNA-based anticancer vac-
cines are most commonly administered 
via the intramuscular route, a setting in 
which multinucleated, elongated muscle 
cells express target antigens to high levels, 
favoring antigen uptake and cross-pre-
sentation by intramuscular DCs. On the 
contrary, the intradermal route allows for 
direct antigen presentation via MHC class 
I mechanism  by DNA-transfected cuta-
neous antigen-presenting cells (APCs), 
including Langerhans cells and DCs.3 We 
therefore hypothesized that chemokine-
mediated recruitment of immature DCs to 
the vaccine administration  site may favor 
direct antigen presentation to T cells by 
vaccinated DCs. We werealso convinced 
that the concurrent recruitment of T cells 
may further promote antigen presentation 
at the vaccination site. In support of these 
notions, we have recently demonstrated 
that the simultaneous recruitment of DCs 
and T cells to the skin prior to  DNA vac-
cination, allows for extranodal antigen 
presentation via MHC class I molecules, 
T-cell activation, expansion, and antigen-
specific cytotoxic immune response in 
both prophylactic and therapeutic settings 
(Fig. 1B).
In summary, further  optimization of 
the priming procedures is likely to allow 
for the efficient recruitment of imma-
ture DCs and naïve T cells to the cuta-
neous tissue, possibly resulting in the 
formation of transient lymph node-like 
structures similar to those observed in 
mucosal tissues,9,10 or for the intratumoral 
accumulation of T cells, 2 are expected 
to improve the efficacy of therapeutic 
DNA-based anticancer vaccines. It is also 
plausible that optimizing the composi-
tion of DNA-based vaccines, for instance 
by including various immunostimulatory 
epitopes or interferon-responsive factors, 
and/or administering them in the con-
text of CTLA4 inhibition would promote 
the DC-mediated activation of tumor-
specific CTLs and hence the elicitation 
of therapeutically relevant tumor-specific 
immune response.
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Figure  1. Intratumoral and intradermal chemokine-enhanced DNa-based anticancer vaccination. (1) Priming of intratumoral (A) and intradermal 
(B) vaccination sites with chemokines. (2) Chemokine-mediated recruitment of T cells alone (A) or accompanied by immature antigen-presenting cells 
(aPCs) (B). (3) administration of DNa-based vaccines into chemokine-primed tissues, leading to enforced antigen expression by immature aPCs, aPC 
maturation, extranodal antigen presentation via MhC class I mechanism , and T-cell activation. (4) Immediate recognition of target (cancer) cells by 
activated antigen-specific cytotoxic T lymphocytes (CTLs) and CTL expansion (A), or emigration of activated CTLs from the skin to antigen-expressing 
neoplastic lesions and relocation of vaccinated aPCs to draining lymph nodes (LNs) and intranodal T-cell activation (B). (5) Killing of antigen-expressing 
target cells by activated CTLs.
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